Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million, to support Teva's anti-IL-15 candidate, TEV-'408 TE ...

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million, to support Teva’s anti-IL-15 candidate, ...

Detailed price information for Royalty Pharma Plc Cl A (RPRX-Q) from The Globe and Mail including charting and trades.

DUBLIN--(BUSINESS WIRE)--Dole plc (NYSE: DOLE) (“Dole” or the “Company”) today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase up ...

This site displays a prototype of a “Web 2.0” version of the daily Federal Register. It is not an official legal edition of the Federal Register, and does not replace the official print version or the ...

The T32 grant provides full-time research training support for post-candidacy predoctoral learners pursuing mentored clinical and translational research or clinical and translational science who are ...

A minor proprietor will observe customers who hyped about their product. They are interested in transforming this excitement into expansion. Exit, such as referral programs, e.g., the idea to give 10 ...

Gain a stronger edge over competitors by using loyalty programs that keep customers coming back and boost your sales. Follow proven steps like point systems and tiered rewards to design a loyalty ...

FT1J is a conveniently-sized, industrially-tough, 4.3-inch, multi-touch display combined with an integrated, full-function controller and onboard, expandable I/O, which makes it ideal for visualizing ...